The Bull Rankings scorecard — our quality-growth score is 72.1 / 100, built from three pillars scored 0–100: Quality 77, Growth 68, Value 71 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 16% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
DaVita’s current price of $189.32 sits on a foundation of solid quality, not on a speculative growth story. Our model scores the company 72.1/100 with a Quality 77, Growth 68, and Value 71. The strongest pillar—Quality—anchors the case. A 77 indicates that the business delivers consistent returns, maintains healthy margins, and has a defensible operating model. The weakest pillar, Growth, signals that the upside is modest; the company is not a high‑growth engine but a mature, cash‑generating franchise.
Three figures reinforce this stance. First, the profit margin of 6% shows that DaVita can squeeze a modest but stable margin in a regulated market. Second, the free‑cash‑flow of $1.6 b in the trailing twelve months demonstrates that the firm is generating real cash that can fund buybacks or debt reduction. Third, the PEG ratio of 0.44 signals that the multiple of 16 is low for the earnings growth analysts expect. Together, these numbers paint a picture of a company that is more about steady, reliable cash than about explosive expansion.
What the business actually is
DaVita operates a nationwide network of kidney dialysis centers that serve patients with chronic kidney failure. The company’s revenue engine is split across several service lines: outpatient dialysis, hospital inpatient dialysis, and home‑based hemodialysis. It also runs clinical laboratories that perform routine tests for dialysis patients and other physician‑prescribed tests for end‑stage renal disease (ESRD) patients. Beyond core dialysis, DaVita offers management and administrative services to outpatient dialysis centers and provides integrated care and disease‑management services under risk‑based and other integrated care arrangements. The primary customers are patients, health plans, and hospitals—entities that rely on DaVita’s expertise to deliver life‑sustaining care.
Why it can (or can't) keep compounding
The durability of DaVita’s cash flow hinges on a few key advantages. First, the regulatory environment creates high entry barriers; new dialysis centers face stringent licensing and quality standards that DaVita has already mastered. Second, the company’s care continuum—patients who start on outpatient dialysis often transition to home or inpatient services—creates cross‑sell opportunities that keep revenue per patient high. Third, the buying back stock signal from our model indicates that management believes the shares are undervalued and that the firm has excess cash to return to shareholders.
Margins remain tight at 6%, but the firm’s return on equity is negative at –110.8%, but that reflects shareholder equity pushed below zero by years of heavy buybacks, not losses. However, the free‑cash‑flow of $1.6 b suggests that the capital intensity is being managed well enough to generate cash. The model’s Durable high returns signal shows returns on capital have held up for years, provided it continues to manage costs and expand its patient base.
The valuation question
The market’s current price implies a P/E of 16 and a PEG of 0.44, which together suggest that the stock is trading at a modest discount to earnings growth expectations. Our reverse‑DCF analysis, however, shows that the price would require a –16% per year free‑cash‑flow growth (in year one, recovering toward 3% a year by year ten) to justify the current valuation. This implied decline is starkly at odds with the 6.4% revenue growth reported for the fiscal year. In other words, the market is already pricing in a scenario where DaVita’s cash flow will shrink, even though revenue is growing modestly. The valuation therefore leans toward pessimism: the price already assumes a negative trajectory that is not supported by the latest earnings data.
The bear case
The most compelling skeptic would point to the negative ROE of –110.8%. Heavy debt‑funded buybacks have pushed equity below zero, leaving little cushion if reimbursement rates tighten or free cash flow weakens. The concrete signal that would confirm this scenario is a continued decline in free‑cash‑flow growth below the 6.4% revenue growth, pushing the implied reverse‑DCF growth further into negative territory.
What would change our mind
- Free‑cash‑flow growth surpasses 10% for two consecutive quarters. Such a jump would demonstrate that the company is not only covering its operating costs but also generating excess cash, shifting the implied growth from –16% to a positive trajectory.
- Profit margin climbs above 8%. An increase in margin would signal better cost control and pricing power, improving the company’s return profile and justifying a higher valuation.
- Shareholder equity turns positive as debt falls. That would make the ROE meaningful again and ease the balance‑sheet worry.
If any of these thresholds are crossed, the narrative would shift from a cautious, quality‑focused view to a more optimistic, growth‑oriented stance. Until then, the evidence points to a company that is solid but not spectacular, and whose current price already discounts a future where cash flow could decline.